|By Marketwired .||
|May 20, 2014 06:00 AM EDT||
BOULDER, CO--(Marketwired - May 20, 2014) - InDevR, a Boulder-based life science company, has received a new NIH SBIR grant to develop an innovative optical system that will automate interpretation of hemagglutination assays. The 2-year Phase 1 grant (R43AI106054) is sponsored by the National Institute of Allergy and Infectious Diseases.
Hemagglutination and hemagglutination inhibition assays are widely used to characterize viruses and related antibodies. For example, the hemagglutination inhibition assay is the gold standard for determining antibody levels produced in response to an influenza vaccine. Both assays rely on manual interpretation of red-blood cell aggregation in the presence of virus, which can lead to error in the measurement. The product in development at InDevR is designed to automate results interpretation and provide a more accurate and precise measurement.
"We are delighted to receive support from NIAID to develop an automated hemagglutination analyzer. This new product is part of our dedicated effort to advance vaccine development and manufacturing through cutting-edge analytical tools that provide improved results at reduced cost," said Dr. Kathy Rowlen, InDevR's CEO.
According to Rowlen, there is a robust National initiative to improve influenza vaccine manufacturing. The hemagglutination inhibition assay has been identified as a problematic step in influenza vaccine characterization. Currently hemagglutination plates are read "by eye", with a user carefully inspecting each well in a 96-well plate and manually recording the results. While many of the assay preparation steps can be automated, plate reading is exclusively manual and represents a bottleneck in the process. The automated hemagglutination analyzer under development at InDevR is based on a proprietary optical design (patent pending) with custom software that will enable rapid assessment of each well in a hemagglutination plate and output of a digital record. Automation of plate reading will eliminate the current bottleneck and streamline analysis.
InDevR has a demonstrated commitment to innovative solutions for the life science industry. With focus on enhancing vaccines and other biotherapeutics, InDevR has emerged as a leader in progressive new analytical technologies that enable accelerated development and manufacturing of these life-saving products. For more information about the company and products, please visit www.indevr.com or call 303-402-9100.
HHS/NIH/NIAID is not responsible for the contents of this release. The statements contained in this release do not constitute endorsement or recommendation by the U.S. Government or HHS.
Akana has announced the availability of version 8 of its API Management solution. The Akana Platform provides an end-to-end API Management solution for designing, implementing, securing, managing, monitoring, and publishing APIs. It is available as a SaaS platform, on-premises, and as a hybrid deployment. Version 8 introduces a lot of new functionality, all aimed at offering customers the richest API Management capabilities in a way that is easier than ever for API and app developers to use.
Aug. 25, 2016 06:00 AM EDT Reads: 1,412
Aug. 25, 2016 03:30 AM EDT Reads: 2,111
Aug. 25, 2016 02:30 AM EDT Reads: 2,141
Aug. 25, 2016 02:15 AM EDT Reads: 460
Aug. 25, 2016 02:00 AM EDT Reads: 1,893
Aug. 25, 2016 02:00 AM EDT Reads: 1,779
Aug. 25, 2016 01:15 AM EDT Reads: 1,602
Aug. 25, 2016 01:00 AM EDT Reads: 1,973
Aug. 25, 2016 12:45 AM EDT Reads: 1,904
Aug. 25, 2016 12:30 AM EDT Reads: 2,074
Aug. 25, 2016 12:00 AM EDT Reads: 2,975
Aug. 24, 2016 10:30 PM EDT Reads: 1,458
Aug. 24, 2016 10:30 PM EDT Reads: 2,013
Aug. 24, 2016 09:15 PM EDT Reads: 1,673
Aug. 24, 2016 04:45 PM EDT Reads: 1,326